Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials

2008 ◽  
Vol 23 (4) ◽  
pp. 181-187 ◽  
Author(s):  
Raymond W. Lam ◽  
Henning F. Andersen ◽  
Alan G. Wade
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Pooled Analysis ◽  
Major Depressive

A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder

2008 ◽  
Vol 23 (4) ◽  
pp. 188-197 ◽  
Author(s):  
Daniel Z. Lieberman ◽  
Stuart A. Montgomery ◽  
Karen A. Tourian ◽  
Claudine Brisard ◽  
Gregory Rosas ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Pooled Analysis ◽  
Controlled Trials ◽  
Major Depressive

scholarly journals Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials

CNS Spectrums ◽  
2014 ◽  
Vol 20 (2) ◽  
pp. 148-156 ◽  
Author(s):  
Stuart A. Montgomery ◽  
Carl P. Gommoll ◽  
Changzheng Chen ◽  
William M. Greenberg
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Extended Release ◽  
Rating Scale ◽  
Pooled Analysis ◽  
Major Depressive ◽  
Double Blind ◽  
Madrs Score ◽  
Wide Range ◽  
Remission Rates

Introduction/ObjectivePost hoc analyses were conducted to evaluate the efficacy of levomilnacipran extended-release (ER) in subgroups of patients with major depressive disorder (MDD).MethodsData were pooled from 5 completed Phase II/III studies. Patients were categorized by sex, age, MDD duration, recurrence of MDD, current episode duration, number of prior episodes, and baseline Montgomery–Åsberg Depression Rating Scale (MADRS) score. Efficacy was evaluated by MADRS least squares (LS) mean change from baseline, response (MADRS improvement ≥50%), and remission (MADRS ≤10).ResultsIn the pooled population, treatment with levomilnacipran ER versus placebo resulted in greater improvement in MADRS score (−15.8 versus −12.9; LS mean difference, −2.9; P < .001) and higher response rates (44.7% versus 34.5%; P < .001). Comparable treatment effects were found in most subgroups. Remission rates in the overall population were higher for levomilnacipran ER versus placebo (27.7% versus 21.5%; P < .05); notably high remission rates were seen in patients with baseline MADRS score < 30 (48.8% versus 28.9%; P < .001).DiscussionClinically meaningful improvements in depressive symptoms were found across subgroups, including statistically significant outcomes for both response and remission.ConclusionLevomilnacipran ER was efficacious across a wide range of MDD patients, including men and women, ages 18–78, with varying histories and symptom severity.

Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis

2017 ◽  
Vol 31 (9) ◽  
pp. 1204-1214
Author(s):  
Raymond W Lam ◽  
Dalia B Wajsbrot ◽  
Ellen Meier ◽  
Elizabeth Pappadopulos ◽  
Joan A Mackell ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Pooled Analysis ◽  
Major Depressive

Predictors of functional response and remission with desvenlafaxine 50 mg and 100 mg: a pooled analysis of randomized, placebo-controlled studies in patients with major depressive disorder

CNS Spectrums ◽  
2019 ◽  
Vol 25 (3) ◽  
pp. 363-371
Author(s):  
Claudio N. Soares ◽  
Dalia B. Wajsbrot ◽  
Matthieu Boucher
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Functional Response ◽  
Functional Outcomes ◽  
Roc Analysis ◽  
Treatment Success ◽  
Pooled Analysis ◽  
Functional Improvement ◽  
Major Depressive ◽  
Early Improvement

Objective.The value of early functional improvement at week 2 for predicting subsequent functional outcomes at week 8 was assessed in a pooled analysis of patients with major depressive disorder (MDD) treated with desvenlafaxine (50 or 100 mg/d) or placebo.Methods.Data were pooled from eight double-blind, placebo-controlled studies of desvenlafaxine 50 mg/d or 100 mg/d for the treatment of MDD. Optimal week-2 improvement thresholds in Sheehan Disability Scale (SDS) score, which best predicted week-8 treatment success, were determined using receiver operating characteristic (ROC) analysis. Four definitions of treatment success were established: (1) functional response, (2) functional/depression response, (3) functional remission, and (4) functional/depression remission. Odds ratios (ORs) of early improvement for prediction (based on thresholds determined in the ROC analysis) of week-8 treatment success were computed using logistic regression models.Results.Functional early improvement thresholds of 17%–32% were predictive of week-8 treatment success across treatment groups and definitions of treatment success. Optimal thresholds were higher for more stringent definitions. Negative predictive value exceeded positive predictive value, indicating that failure to achieve early functional improvement was more informative about later treatment success than was the achievement of early functional improvement. Early change in SDS was a highly significant predictor of functional response/remission (ORs, 4.981–8.737; all p < 0.0001); the interaction between treatment and early functional improvement was not significant.Conclusion.Early improvement in SDS total score was predictive of functional outcomes for patients treated with desvenlafaxine 50 mg, desvenlafaxine 100 mg, or placebo.

Sign in / Sign up

Export Citation Format

Share Document